Cannabis Science Brings CS-TATI-1 to the FDA with Historic Collaborative Drug Development Deal With IGXBio and Its GenePro®, a DNA-Based Immunotherapeutic that Recently Received FDA Approval to Enter into Human Trials
COLORADO SPRINGS, Colo., May 27, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabis-based medicine and related consulting, has announced a Historic Collaborative Drug Development deal with IGXBio and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies intend to develop a joint protocol to demonstrate potential synergistic effects of their respective drug candidates in HIV, as well as potential new drug candidates.
Mr. James Laufenberg, President and CEO of IGXBio, stated, "I am very excited about this collaboration with Cannabis Science, a company based on our own values of serving the unmet needs of HIV positive patients. The GenePro® technology has been published in over 150 scientific journals. GenePro® is intended to promote an anti-HIV immune response to facilitate virus control in HIV-infected subjects. The pre-clinical development to date has been largely funded by $21 million in NIH grants. Our collaboration with Cannabis Science is designed to create new products for clinical development and commercialization in addition to utilizing GenePro® in a Phase I/IIa clinical trial."
"Inflammation is the body's immune response to HIV that occurs at even low levels of HIV replication. It is a major contributor to the co-morbidities that promote morbidity and mortality in people with HIV, despite successful antiretroviral therapy such as heart disease, bone disease and cancers. If inflammation can be lowered or eliminated along with HIV viral replication it will successfully improve the health and extend the lives of HIV-positive people. By partnering CS-TATI-1 and GenePro® we believe this is possible," stated Dr. Roscoe M. Moore, Jr., DVM, MPH, Ph.D., DSc., Former Asst. US Surgeon General and Cannabis Science Special Senior Advisor and Member of the Company's Scientific Advisory Board.
"The collaboration between IGX Bio and CBIS is intended to help provide new insights into the role of inflammation and therapeutic vaccination of HIV as a critical step for optimizing effective treatments for AIDS patients in various resource settings. These studies will provide a scientific evaluation of GenePro® and CS-TATI-1 to demonstrate the enhanced potential of therapeutic vaccination and the anti-inflammatory effects of cannabinoids to deter disease progression in AIDS patients unable to achieve control HIV replication," stated Mr. Raymond C. Dabney, Cannabis Science, Inc., President & CEO, Co-Founder.
IGXBio is a privately held clinical stage biotechnology company developing advanced DNA immunotherapies for HIV infection, based in Fairway, KS, USA. The Company's lead product candidate, GenePro®, is an immune-therapeutic generating non-infective viral like particles by incorporating a proprietary DNA lentiviral composition that yields high levels of gene expression and non-infectious HIV protein production, inducing robust antibody and cellular immune responses. Published data in non-human primates has demonstrated production of CD8+ memory cells similar to those produced by Elite Controllers of HIV. These are individuals who represent a small percentage of the population who control HIV progression without having therapeutic drugs on board. GenePro® has an open IND and ready to advance to human trials.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.